CITRASATE™
Citrasate™, an exclusivity of Nipro Medical Europe, is an acid concentrate for dialysis that contains 0.8 mmol/l of citric acid and 0.3 mmol/l of acetate, instead of the traditional 3 mmol/l of acetic acid contained in standard acid concentrates.
The anticoagulant properties of citric acid, combined with a lower volume of acetate, improve the biocompatibility and dialysis adequacy while reducing the use of heparin.1-3
With our two manufacturing sites, MTN in Germany and NRS in Spain, we can ensure a continuous supply, offering a wide range of Citrasate to an extended geographical area.
Available in mixing ratio 1:44, the Citrasate comes in bags, canisters, politainers (soft container), and large volume bag-in-box – that latter of which links directly to dialysis machines.
- Unique citric acid concentrate with a reduced amount of acetate
- Improved biocompatibility and dialysis adequacy1-2
- Variety of single-use or multiple-use container types and sizes to match different needs
- Easy to handle, store, and dispose of
- Large volume bag-in-box to reduce environmental impact and minimize handling4
* Availability of products might vary per country. Please contact your local Nipro representative for specifications, minimum order quantities, and availability.
Footnotes
- Pizzarelli F, et al. Citrate high volume on-line hemodiafiltration modulates serum Interleukin-6 and Klotho levels: the multicenter randomized controlled study "Hephaestus". J Nephrol. 2021
- Sands JJ et al. Effects of citrate acid (Citrasate) on Heparin N Requirements and hemodialysis Adequacy: A multicenter, prospective noninferiority trial. Blood. Purif. 2012;33:199-204
- Kossmann RJ et al. Fifty-five percent heparin reduction is safe with Citrasate dialysate in chronic dialysis Patients. ASN Renal week Meeting, 2006, Abstract No. 708 Reduce heparin
- Evaluation by Aural organization. 2022. Report available upon request.
